Pyxis Oncology, Inc. (PYXS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pyxis Oncology, Inc. (PYXS:NASDAQ), powered by AI.

Current Price
$1.75
Sector
Healthcare
What is the Pyxis Oncology, Inc. stock price forecast?

Pyxis Oncology, Inc. is currently trading at $1.75. View real-time AI analysis on Alpha Lenz.

What is Pyxis Oncology, Inc. insider trading activity?

View the latest insider trading data for Pyxis Oncology, Inc. on Alpha Lenz.

What is Pyxis Oncology, Inc.'s P/E ratio?

View Pyxis Oncology, Inc.'s valuation metrics on Alpha Lenz.

Pyxis Oncology, Inc.

NASDAQ · PYXS
$1.75+0.01(+0.57%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Pyxis Oncology, Inc.'s future dividend policy...
Alpha Chat Insight

Pyxis Oncology, Inc.'s ROE is -91.4%. Explore profitability and growth together.

Ask for details

Company Overview

Pyxis Oncology Inc. is a biopharmaceutical company dedicated to developing an innovative portfolio of next-generation medicines targeting cancer. The primary focus of the company lies in harnessing proprietary technologies to advance novel antibody-based therapeutics. By emphasizing precision medicine, Pyxis Oncology aims to create therapies that improve the standard of care for cancer patients, addressing specific unmet medical needs. The company operates in the highly specialized pharmaceutical and biotechnology sectors, where breakthrough treatments can significantly impact patient outcomes. Its ongoing research and development efforts place Pyxis Oncology among the trailblazers in the medical industry, contributing to the expansion of targeted therapy options. With its dedication to pioneering drug discovery, Pyxis Oncology plays a crucial role in the evolving landscape of cancer treatment, which is a critical component of the broader healthcare and life sciences markets. The company's mission to transform the oncology therapeutic field underscores its importance in the pursuit of comprehensive cancer care solutions.

CEODr. Lara S. Sullivan M.D., MBA
SectorHealthcare
IndustryBiotechnology
Employees44

Company Statistics

FY 2025

Profile

N/AMarket Cap
$13.86MRevenue
0.00Shares Out
44Employees

Margins

82.77%Gross
-576.63%EBITDA
-609.18%Operating
-564.55%Pre-Tax
-574.55%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-64.03%ROA
-91.43%ROE
-67.89%ROIC

Financial Health

$15.42MCash & Cash Equivalents
$22.69MNet Debt
71.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Pyxis Oncology, Inc. (ticker: PYXS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 44 employees.

The current price is $1.75 with a P/E ratio of -x and P/B of -x.

ROE is -91.43% and operating margin is -609.18%. Annual revenue is $14M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Pyxis Oncology, Inc. (PYXS) Stock Forecast 2026 $1.75 — Price, Financials & Analyst Targets | Alpha Lenz